Neuroendocrine Tumors, as genome-wide studies have reported it: 14 positions from 1 study, the largest recording 751 cases and 572,091 controls (African American or Afro-Caribbean ancestry, European ancestry). Built from the GWAS Catalog's records and rebuilt when a new position is reported; the figures are the studies'.
1 study in the GWAS Catalog report 14 positions for Neuroendocrine Tumors, which the catalogue files as "Neuroendocrine tumors (PheCode 209)". MyGeneLog follows the condition as positions arrive: code builds this page from the records, adds each new position when it is reported, and writes no sentence of its own beyond them.
Verma A et al. 2024, in Science — Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. The catalogue records its sample as 751 cases and 572,091 controls (African American or Afro-Caribbean ancestry, European ancestry). From it, 14 positions on this page: rs183808807 (LINC01572), rs543107477 (MPP7), rs183587406 (ITGB4), rs551907375 (ZCCHC24), rs530143739 (ALPL), rs553574525 (MCTP1), rs555554410 (near PMM2P2), rs528111636 (GATD3), and 6 more. PMID:39024449.
The 14 positions lie in or near 14 genes: LINC01572, MPP7, ITGB4, ZCCHC24, ALPL, MCTP1, PMM2P2, GATD3, SLC35F3, SGPL1, RNU6-1120P, GCNT2, ALDH18A1, DRICH1. A gene named here is the catalogue's mapped location for a position, not a mechanism; the studies are cited above so that a reader can go to them.
Of all these, rs183808807 in LINC01572 carries the strongest signal: P = 2 × 10-13, in Verma A et al. 2024.
Association records say which positions differ, on average, between people with Neuroendocrine Tumors and people without. They do not describe the condition, say how common it is, or tell anyone what to do, so this page does not either. For a single position, open its variant page: it gives that study's record in fixed sentences, with ClinVar's where there is one.
A genotype does not diagnose Neuroendocrine Tumors; a clinician does. No guideline uses the 14 variants on this page to predict it, screen for it or confirm it.
This page was assembled by code from association records. It holds no clinical guidance, because its sources hold none: a genome-wide study reports which positions differ between people with a condition and people without, at the population level, and that is all this page repeats. A question about a symptom, a test or a treatment belongs with a clinician.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Neuroendocrine Tumors comes down to these specific, well-studied positions — not a diagnosis.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Neuroendocrine Tumors. MyGeneLog™. https://www.mygenelog.com/conditions/neuroendocrine-tumors
Neuroendocrine Tumors is the condition the GWAS Catalog files under "Neuroendocrine tumors (PheCode 209)". This page does not define it in its own words; it lists what genome-wide studies have reported: 14 positions from 1 study, with each study's sample and citation.
Genes play a part: 14 positions have been linked to it, the largest study recording 751 cases and 572,091 controls (African American or Afro-Caribbean ancestry, European ancestry). But each is a common variant of small effect, and a link found across a population does not cause the condition in any one person.
The positions lie in or near 14 genes: LINC01572, MPP7, ITGB4, ZCCHC24, ALPL, MCTP1, PMM2P2, GATD3, SLC35F3, SGPL1, RNU6-1120P, GCNT2, ALDH18A1, DRICH1. A mapped gene is the catalogue's location for a position, not a mechanism.
No. They are population-level findings of small effect. Neuroendocrine Tumors is diagnosed by a clinician, and no guideline uses a genotype to predict it.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.